MBX Biosciences, Inc. (MBX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$48.46-7.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · MBX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -44.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
MBX — director transition
Dated 2026-10-22
Director — Peter Radovich: The filing discloses the routine appointment of a new independent director to fill a board seat, which is a standard governance action rather than an executive departure.
Why it matters: The pivotal trial is now underway. Steady enrollment supports the planned path to test canvuparatide in a larger study.
Supportive ifMBX reports active recruitment and screening in the Phase 3 oPTimize trial, with no disclosed pause or delay.
Worry ifMBX reports a trial pause, slow recruitment, or a delay to the Phase 3 study timeline.
Why it matters: MBX reported $418.6 million in cash and expects funds to last into 2029. Higher spending or a shorter runway could raise funding risk.
Worry ifMBX reports that its cash and investments are no longer expected to fund operations into 2029.
Less concerning ifMBX says its current cash and investments are expected to fund operations into 2029.
Why it matters: This Phase 1 update tests whether monthly dosing can work beyond the small first cohort. Weight loss and side effects will be key measures.
Watch forThe first Part C cohort shows weight loss at 12 weeks and no serious safety concern, with data reported in Q4 2026.
Also watch forThe data show little or no weight loss, serious safety concerns, or a delay past Q4 2026.
Why it matters: MBX 6180 adds a triple-agonist obesity drug to the pipeline. The planned data can show whether it is ready for further testing.
Supportive ifMBX shares early data on MBX 6180 at a scientific meeting in Q4 2026. It says IND-enabling studies are underway.
Worry ifThe data are delayed past Q4 2026, or MBX reports that IND-enabling studies have stopped.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$250 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $736 loss on $10,000 · 7.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,760 loss on $10,000 · 37.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.